<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182791</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1245</org_study_id>
    <nct_id>NCT02182791</nct_id>
  </id_info>
  <brief_title>Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women</brief_title>
  <official_title>An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE® ) and Ethinyl Estradiol/Norethindrone [ORTHO-NOVUM® 1/35 (21 Pack)] in HIV-1 Infected Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the effects of nevirapine treatment on the pharmacokinetics of ethinyl&#xD;
      estradiol (EE)/norethindrone (NET).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <primary_completion_date type="Actual">April 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (Area under the plasma concentration time curve) of ethinyl estradiol/norethindrone (EE/NET)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 0 and day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration) of EE/NET</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 0 and day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of maximum concentration) of EE/NET</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 0 and day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCss (Area under the concentration time curve at steady state) of nevirapine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration) of nevirapine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin (minimum observed concentration) of nevirapine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cl/F (Oral clearance) of nevirapine</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 15, 24, and 34 hours post dose on day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 59 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Nevirapine tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once a day (q.d.) Day 2-15,&#xD;
twice a day (b.i.d.) Study day 16-30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EE/NET tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose on Study Day 0 and 30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <arm_group_label>Nevirapine tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE/NET</intervention_name>
    <arm_group_label>EE/NET tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients between the ages of 18 and 65 years&#xD;
&#xD;
          -  Plasma HIV-1 RNA &lt;= 400 copies/mL, documenting HIV-1 infection, within 28 days prior&#xD;
             to Study Day 0&#xD;
&#xD;
          -  Lymphocytes Expressing CD4+ Surface Marker (CD4+ cell count) &gt;= 100 cells/mm³ within&#xD;
             28 days prior to Study Day 0&#xD;
&#xD;
          -  Patients who meet the following laboratory parameter:&#xD;
&#xD;
               -  Lymphocyte count &gt;= 1000 cells/mm³&#xD;
&#xD;
               -  Hemoglobin &gt;= 9.0 g/dl (men and women)&#xD;
&#xD;
               -  Platelet count &gt;= 75000 cells/mm3&#xD;
&#xD;
               -  Alkaline Phosphatase &lt;= 3.0 times the upper limit of normal&#xD;
&#xD;
               -  Serum Glutamic-Oxaloacetic Transaminase (SGOT) and Serum Glutamic-Pyruvic&#xD;
                  Transaminase (SGPT) &lt;= 3.0 times the upper limit of normal&#xD;
&#xD;
               -  Total bilirubin &lt;= 1.5 times the upper limit of normal&#xD;
&#xD;
               -  Creatinine &lt;= 2mg/dL&#xD;
&#xD;
          -  Female patients of reproductive potential must be willing to use a reliable method of&#xD;
             double-barrier contraception (such as diaphragm with spermicidal cream or jelly, or&#xD;
             condoms with spermicidal foam)&#xD;
&#xD;
          -  Patients who are informed of and willing and able to comply with the investigational&#xD;
             nature of the study and had signed a written consent in accordance with institutional&#xD;
             and federal guidelines&#xD;
&#xD;
          -  Patients who have been on stable antiretroviral therapy (no changes in medication or&#xD;
             dose) for at least thirty days prior to study entry and who will continue on&#xD;
             background during study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Patients requiring systemic treatment with corticosteroids or drugs known to be&#xD;
             hepatic enzyme inducers or inhibitors within 14 days of stud entry (Study Day 0). Such&#xD;
             substances in these categories include: macrolide antibiotics (erythromycin,&#xD;
             clarithromycin), azole antifungals (ketoconazole, fluconazole, itraconazole) rifampin,&#xD;
             rifabutin, and phenytoin&#xD;
&#xD;
          -  Patients receiving any investigational drug within 30 days of the first dose of study&#xD;
             medication and any antineoplastic agent or radiotherapy other than local skin&#xD;
             radiotherapy treatment within 12 weeks before starting study medication&#xD;
&#xD;
          -  Patients with malabsorption, severe chronic diarrhea or patients unable to maintain&#xD;
             adequate oral intake&#xD;
&#xD;
          -  Patients with a history of intravenous drug abuse, alcohol or substance abuse&#xD;
             considered by the Investigator and Boehringer Ingelheim Pharmaceutical Incorporated&#xD;
             (BIPI) Medical Monitor to be a significant impairment to health and compliance&#xD;
&#xD;
          -  Patients undergoing treatment for an active infection&#xD;
&#xD;
          -  Patients with hepatic insufficiency due to cirrhosis&#xD;
&#xD;
          -  Patients with renal insufficiency&#xD;
&#xD;
          -  Patients who are heavy smokers (e.g. &gt; 20 cigarettes per day)&#xD;
&#xD;
          -  Patients currently taking Norvir® (Ritonavir) or Rescriptor® (Delavirdine)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1100/1100.1245_U00-3030.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

